
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
| Revenue (TTM) | $4.03B |
| Gross Profit (TTM) | $1.39B |
| EBITDA | $889.62M |
| Operating Margin | 15.90% |
| Return on Equity | -5.87% |
| Return on Assets | 4.26% |
| Revenue/Share (TTM) | $81.96 |
| Book Value | $61.05 |
| Price-to-Book | 3.67 |
| Price-to-Sales (TTM) | 2.74 |
| EV/Revenue | 3.394 |
| EV/EBITDA | 47.04 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | 1.20% |
| Shares Outstanding | $48.17M |
| Float | $47.65M |
| % Insiders | 0.64% |
| % Institutions | 123.89% |
Volatility is currently expanding

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?

Charles River Laboratories International, Inc. CRL is well-poised to grow in the coming quarters owing to the strength of its Research Models and Services (“RMS”) business and broader CRADL adoption. Strategic deals continue to broaden its capabilities while streamlining its portfolio.

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRL and any ticker you trade — then tracks every position and per-strategy win rate.